As precision medicine reshapes the treatment paradigm for oncology and beyond, Antibody-Drug Conjugates (ADCs) and Radiopharmaceutical Drug Conjugates (RDCs) have emerged as powerful therapeutic modalities that unite specific targeting with potent cytotoxic or radiotherapeutic payloads. Yet the path from bench to clinic for ADCs and RDCs is notoriously complex—requiring cutting-edge conjugation chemistry, robust formulation platforms, and stringent GMP compliance.
Litchlab, a leading CDMO specializing in targeted nanomedicines, is redefining how next-generation ADCs and RDCs are developed and manufactured. By integrating conjugation technologies with advanced delivery systems such as liposomes and polymeric nanoparticles, Litchlab delivers an end-to-end CDMO solution from early-stage screening through clinical production and regulatory submission.
Supports diverse antibody formats: full-length IgG, scFv, Fab, bispecifics, VHH
Multiple conjugation chemistries:
Site-specific: Thiol-maleimide, SPAAC click, enzyme-based (Sortase A, TGase)
DAR optimization (DAR 2/4/8) for safety and efficacy balance
Modular PEG linkers: Tunable spacing, orientation, and density for optimal binding
Dual-targeting conjugation systems for addressing tumor heterogeneity
Payload library:
Cytotoxics: MMAE, SN38, DM1, PBDs
Radioisotopes: Lu-177, Zr-89, Ac-225, I-131
Novel payloads: STING agonists, kinase inhibitors, immune activators
Linker systems:
Cleavable: Acid-sensitive, esterase-labile, disulfide-sensitive
Non-cleavable: For sustained intracellular retention
Smart linkers: pH-, enzyme-, and redox-responsive
Lipo-ADC / Lipo-RDC Platforms:
Liposome-conjugated systems improve plasma stability and tumor penetration
Polymeric micelles and nanogels:
Support controlled release and payload shielding (esp. for radiotherapeutics)
High-activity payload stabilization:
Lyophilization, instant encapsulation, and shielding technologies for radionuclide handling
Scalable from milligram to commercial batches
Includes antibody expression, linker synthesis, payload loading, conjugation, sterile fill-finish
Microfluidic conjugation systems: High homogeneity and reproducibility
Lyophilized and terminally sterilized formulations supported
cGMP facilities:
Class A/B cleanrooms
Radiation-safe handling and waste containment infrastructure
| Indication | Drug Format | Target(s) | Delivery System |
|---|---|---|---|
| HER2+ Breast Cancer | Lipo-ADC (DM1) | HER2 | Liposome-conjugated ADC |
| Hepatocellular Carcinoma | RDC (Lu-177-siRNA) | ASGPR, αvβ3 | Radiolabeled polymeric nanoparticles |
| Neuroendocrine Tumors | RDC (Ac-225) | SSTR2 | Chelator-labeled lipid nanoparticles |
| Pancreatic Cancer | Dual-target Lipo-RDC | EGFR + PD-L1 | Dual-ligand liposomes with isotope |
| AML (Acute Myeloid Leukemia) | ADC (SN38) | CD33 | Polymeric nanocarrier with cleavable linker |
As the field moves from proof-of-concept to commercial scalability, Litchlab offers a next-generation CDMO model—not only delivering high-quality conjugates, but co-engineering smart therapeutic architectures with its partners. From payload-linker compatibility to regulatory strategy, Litchlab serves as a trusted ally in transforming complex designs into first-in-class clinical assets.
Future roadmap includes:
Nucleic Acid Conjugates (NACs)
Immune-Stimulating ADCs (ISACs)
Dual payload ADCs (e.g., chemo + RNAi)
📧 Contact: RD1@litchlab.com
📩 Learn more or inquire about a project: www.litchlab.com
